FDA Finds No Major Drug Deficiencies for Ketamine ANDA, Commits to Expedited Review for Packaging Issue

summarizeSummary

NRX Pharmaceuticals received positive first-round FDA feedback on its ketamine ANDA, with no drug-related deficiencies, and the FDA committed to an expedited review for a packaging issue.

check_boxKey Events · Product Development and Regulatory · NRXP

• Positive Drug Component Review

  The FDA advised that there were no major deficiencies related to the drug components of the preservative-free ketamine ANDA.

• Packaging Deficiency Identified

  A major deficiency was identified related to the twist-off cap of the product's luer lock vial, with concerns about potential deformation in clinical use.

• Expedited Resolution Path

  Following a clarification meeting, the FDA committed to immediately reinitiate review of the ANDA and complete it in the shortest-possible review cycle, recognizing ketamine as a strategic drug on the shortage list.

• Management Optimism for 2026 Sales

  Management is optimistic that the packaging concern will be resolved in a timely manner, consistent with first commercial sales in 2026.

auto_awesomeAnalysis · NRXP · Life Sciences

The FDA completed its first-round review of NRX Pharmaceuticals' preservative-free ketamine ANDA, finding no major deficiencies related to the drug components. While a major deficiency was identified concerning the product's vial cap, the FDA has committed to an immediate reinitiation of review and a 'shortest-possible review cycle' due to ketamine being a strategic drug on the shortage list. This suggests a clear, expedited path to resolving the packaging issue, which is crucial for the company's goal of commercial sales in 2026, especially given its prior 'going concern' warning.